Lupin announced the launch of Mycophenolic Acid Delayed-Release Tablets USP, 180 mg and 360 mg.
The announcement was made today, 6 April 2020. Indian stock markets are closed today, 6 April 2020 on account of Mahavir Jayanti.
Shares of the Lupin ended 13.05% higher at Rs 654.80 on Friday, 3 April 2020.
Lupin's alliance partner Concord Biotech Limited (Concord) had received an approval from the United States Food and Drug Administration (USFDA) earlier.
Mycophenolic Acid Delayed-Release Tablets USP, 180 mg and 360 mg, is the generic equivalent of Myfortic Delayed-Release Tablets, 180 mg and 360 mg, of Novartis Pharmaceuticals Corporation.
Myfortic had an annual sales of approximately $156 million in the U.S. (IQVIA MAT February 2020).
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa and across Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)